Incidence and Factors Related with Improved Chest Radiographic Findings in Covid-19 Patients after Favipiravir Treatment at the second Hospital Field of Kasetsart University: Suphanburi
Keywords:
Covid-19 patients, Hospital field, chest radiograph, Rama Co-RADS, C-reactive protein (CRP), FavipiravirAbstract
Background: Coronavirus disease 2019 (COVID-19) is an emerging disease. Guidelines for medical practice advise patients with mild symptoms to consider favipiravir as soon as possible. But there are risk factors for severe diseases. For example, age > 6years, chronic obstructive pulmonary disease (COPD) combined chronic lung disease, stroke, uncontrolled diabetes, obesity (BMI ≥ 30 kg/m2), room air SpO2 ≤ 96% or found to have SpO2 while exertion decreases ≥ 3% of the first measured value (Exercise-induced hypoxia), which may require regular hospitalization or consider corticosteroid with favipiravir.
Objective: The purpose of this study was to investigate and analyze the factors associated with the improvement of chest radiographic findings in COVID-19 patients following favipiravir treatment at the second Hospital Field of Kasetsart University: Suphanburi.
Method: A retrospective cohort analytic study was performed by collecting data from the medical records or electronic health records of COVID-19 patients who enter to the second Hospital Field of Kasetsart University: Suphanburi. The medical data and chest radiographic reports were collected during July 11, 2021- September 30, 2021. By using the chi-square test, independent t-test, univariate, and multivariate logistic regression, data were analyzed to determine the percentage, mean statistic, and related factor between sex, age, underlying disease, body mass index, clinical level of C-reactive protein, and radiographic findings.
Results: The average age of the 151 patients enrolled in the study was 44.21 years, there were females 62.90% and 74.17% had no underlying disease. The C-reactive protein level levels greater than or equal to 15 mg/L had a statistically significant improvement in the change on chest radiographs (p = .009).
Conclusion: Level of C-reactive protein levels greater than or equal to 15 mg/L had a statistically significant improvement in the change on chest radiographs.
References
Suwatanapongched T, Nitiwarangkul C, Sukkasem W, Phongkitkarun S, et al.Rama Co-RADS: Categorical Assessment Scheme of Chest Radiographic Findings for Diagnosing Pneumonia in Patients With Confirmed COVID-19. Rama Med J. 2021;44(2):50-62.
Suwatanapongched T, Nitiwarangkul C, Sukkasem W, Phongkitkarun S. Categories and The corresponding levels of suspicion for pulmonary involvement for rapid triage of patients with confirmed COVID-19 by chest radiograph or Rama Co-RADS (Version 1). [Internet] [cited 2021 May 25]. Available from: https://www.rama.mahidol.ac.th/radiology/ th/knowledge/radiology/05092021-1753-th
Ratnarathon A. Clinical characteristics and chest radiographic findings of coronavirus disease 2019 (COVID-19) pneumonia at Bamrasnaradura Infectious Diseases Institute. Dis Control J.2020;46(4):540-50.
Limcharoen S, Intrarak J. Imaging in COVID-19. BJM.2020;7(1):103-112.
Department of Medicine Services, Ministry of Public Health. Guidelines on triage individuals with confirmed COVID-19 in Bangkok [Internet]. 2021 [cited 2021 May 25]. Available from: https://covid19.dms.go.th/Content/Select_Landding_page?contentId=120
Department of Medicine Services, Ministry of Public Health. Guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for COVID-19 [Internet]. 2021 [cited 2021 May 25]. Available from: https://ddc.moph.go.th/viralpneumonia/eng/file/guidelines/g_CPG_06may21.pdf
R8way, Ministry of Public Health. Case Management COVID-19 [Internet]. 2021 [cited 2021 May 25]. Available from: https://r8way.moph.go.th/r8way/covid-19
Department of Medicine Services, Ministry of Public Health. Guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for COVID-19 [Internet]. 2021 [cited 2021 Sep 10]. Available from: https://ddc.moph.go.th/viralpneumonia/eng/file/guidelines/g_CPG_COVID_v.17_n_20210804.pdf
สกันยา โกยทรัพย์สิน. ลักษณะภาพถ่ายรังสีปอดของผู้ป่วย COVID-19 ในโรงพยาบาลป่าตอง.วารสารวิชาการสาธารณสุข. 2564;30(1):26-32.
วริสรา กิตติวรพงษ์กิจ. การดำเนินโรคและการเปลี่ยนแปลงชั่วคราวที่พบในภาพรังสีทรวงอกของผู้ป่วยติดเชื้อโควิด 19 ที่โรงพยาบาลพะเยา. วารสารโรงพยาบาลนครพิงค์. 2564;12(1):149-167.
Sergio G., Vancheri V., Giovanni S., Francesco B., et al. Radiographic findings in 240 patients with covid-19 pneumonia: time-dependence after onset of symptoms. Eur Radiol .2020;30:6161–616.
Audrey E., Sonum N., Sarayu R., Dalia S K., et al. Review of radiographic findings in COVID-19. World J Radiol. 2020;12(8):142-155.
Scott S., Fernando U. K., Suhny A., Sanjeev B., et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19: Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA-Secondary Publicatiom. J Thorac Imaging. 2020;35(4):219-27.
Liqa A. R., Eyhab E., Musaab K., Yousef K. Chest x-ray findings and temporal lung changes in patients with COVID-19 pneumonia. BMC Pulmonary Medicine. 2020;20(1):1-9.
Chamorro EM, Tascón AD, Sanz LI, Vélez SO, Nacenta SB. Radiologic diagnosis of patients with COVID-19. Radiología (English Edition). 2021;63(1):56-73.
Fujii S, Ibe Y, Ishigo T, Inamura H, Kunimoto Y, Fujiya Y, Kuronuma K, Nakata H, Fukudo M, Takahashi S. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. Journal of Infection and Chemotherapy. 2021 Jul 1;27(7):1051-7.
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases. 2021;102:501-8.
Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FF, El Ghafar MS, Soliman S, Elbahnasawy M, Badawi R, Tageldin MA. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Archives of Virology. 2021;166:949-54.
Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Karapetian RN, Kravchenko DV, Lomakin NV. AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial. Clinical Infectious Diseases. 2021;73(3):531-4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Hua-Hin Hospital
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์ในวารสารหัวหินเวชสาร เป็นลิขสิทธิ์ของโรงพยาบาลหัวหิน
บทความที่ลงพิมพ์ใน วารสารหัวหินเวชสาร ถือว่าเป็นความเห็นส่วนตัวของผู้เขียนคณะบรรณาธิการไม่จำเป็นต้องเห็นด้วย ผู้เขียนต้องรับผิดชอบต่อบทความของตนเอง
